Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels, GPCRs, and transporters. | Veneno Technologies is a Japan-origin deep-tech biotech company founded in 2020 and built around a proprietary Disulfide-Rich Peptide, or DRP, discovery platform. Based on scientific achievements originating from AIST, the company has established an integrated end-to-end system combining design, screening, functional evaluation, and production of DRPs through its proprietary Veneno Suite and PERISS platform. Veneno aims to create a new peptide modality for targets that have remained difficult to address with conventional small molecules or antibodies. The company’s core strength lies in its ability to translate the intrinsic biological advantages of naturally occurring DRPs into an industrial discovery engine. Because DRPs possess multiple disulfide bonds and a conformationally constrained structure, they can offer high stability, protease resistance, thermal robustness, and strong target selectivity. These properties make DRPs especially attractive for membrane proteins and other challenging target classes where conventional modalities often face limitations in selectivity, penetration, or functional control. Veneno is leveraging this differentiated biology to generate novel therapeutic candidates with the potential to open new mechanisms of action in previously hard-to-drug disease areas. Current Strategic Focus Areas 1) Ri-DRP drug discovery: Veneno is actively advancing Ri-DRP programs in which DRPs are conjugated with radioactive payloads, including alpha-emitting isotopes. By combining the high target selectivity and compact size of DRPs with radiopharmaceutical design, the company aims to enable precise tumor targeting and differentiated payload delivery beyond what is often achievable with conventional antibody-based radioconjugates or small-molecule radiopharmaceuticals. Ri-DRP represents a highly strategic direction for Veneno, particularly in oncology, where target-specific delivery, tissue distribution, and therapeutic precision are central to next-generation drug design. 2) Functional development of DRPs as next-generation antibody-like molecules: Veneno positions DRPs not simply as peptides, but as a next-generation functional modality that can complement and, in selected settings, outperform antibodies. The compact and highly structured nature of DRPs allows precise interaction with biologically important surfaces while maintaining strong stability and selectivity. This creates opportunities in areas where antibodies may be constrained by tissue penetration, epitope accessibility, or molecular size. Veneno is therefore developing DRPs as next-generation antibody-like agents for membrane proteins, complex interaction interfaces, and disease areas that require finely tuned molecular recognition. 3) DRP drug discovery for membrane proteins including ion channels, GPCRs, and transporters: Veneno’s discovery platform is particularly differentiated in the generation of functional DRPs against membrane proteins that have historically been difficult to drug. Through the proprietary PERISS method, the company can identify inhibitor, activator, and binder DRPs for ion channels, GPCRs, transporters, and related membrane targets. These target classes are biologically important across oncology, inflammation, pain, cardiometabolic disorders, and other major therapeutic areas, yet they remain challenging because small molecules can suffer from off-target effects and antibodies often have limited access to the relevant target surfaces. Veneno is using DRPs to bridge this gap and unlock first-in-class opportunities in membrane protein drug discovery. Through these three focus areas, Veneno Technologies is positioning DRPs as a scalable platform for next-generation therapeutics spanning membrane protein drug discovery, antibody-like functional molecules, and radiopharmaceutical innovation. At BIO International 2026, the company is seeking global collaboration opportunities including joint research, co-development, licensing, and strategic partnerships with pharmaceutical companies, biotech innovators, radiopharmaceutical developers, and research institutions.
Sussex Research Laboratories Inc.
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in empowering therapeutic innovation through glycoscience. The company applies its expertise in glycodesign, glycan and glycoconjugate synthesis, and linker chemistries across a wide range of therapeutic areas, including vaccine development, protein and antibody engineering, and targeted drug delivery. With 30 years of experience as a Contract Research & Development (CRO) service provider, Sussex Research supports pharmaceutical and biopharmaceutical partners in applying glycotechnology to next-generation therapeutics, including oligonucleotide, peptide, protein, lipid, and small-molecule modalities, as well as lipid nanoparticle (LNP) technologies for modern drug design and delivery. The company is also widely recognized for its enabling product portfolio of advanced glycans, glycopeptides, glycoconjugates, and targeting ligand/linker systems.
Scienta Lab
Scienta is a techbio company founded in 2021, dedicated to transforming drug development in immunology and inflammation. By combining proprietary disease-specific data assets with next-generation foundation model AI, Scienta bridges the translational gap that has long made I&I drug development among the most costly and failure-prone in the pharmaceutical industry. Despite decades of research and significant investment, the majority of immunology drug candidates still fail in clinical trials, largely due to poor translation from animal models to human patients. Phase II failure rates in I&I remain stubbornly high, driven by an inability to reliably predict which patients will respond to a given therapy before a costly trial begins. Scienta was built to address this challenge at its root. At the core of Scienta’s platform is EVA, the first cross-species, multimodal foundation model dedicated exclusively to immunology and inflammation. EVA learns from ImmunAtlas, Scienta’s proprietary curated database aggregating over 600,000 patient and biosample profiles across more than 30 immune-mediated diseases, integrating clinical, transcriptomic, histological, and proteomic data from 70+ tissues and more than 3 billion biological data points. EVA operates across the full drug development pipeline. At the discovery stage, it enables zero-shot target efficacy and gene function prediction to identify and prioritize the most promising therapeutic mechanisms. In preclinical development, it models cross-species and cross-disease molecular perturbations to anticipate how a drug candidate will impact immune networks in humans, going beyond what animal models alone can reveal. At the clinical stage, it supports patient stratification, treatment response prediction, and disease activity forecasting to identify the right patients for the right therapies before trials begin. In independent benchmarking across 39 immune-specific tasks spanning the drug development pipeline, EVA achieved state-of-the-art results, outperforming both generalist biological foundation models and conventional baselines. These results have been validated through peer-reviewed publications and presentations at leading biomedical and AI conferences. Scienta’s technology has been validated in concrete biopharma partnerships, with applications spanning dermatology, gastroenterology, rheumatology and neurology. Unlike generalist AI platforms or single-cell-focused tools, Scienta combines two capabilities rarely found together: high translational capability bridging preclinical to clinical development, and disease-specific explainability. Models are built to be interrogated, providing mechanistic interpretability that helps scientists understand why a prediction is made. This positions Scienta uniquely at the intersection of molecular precision and systemic, patient-level modeling. Scienta was co-founded by Camille Bouget (CEO, PharmD, previous experience across Sanofi, Sandoz, and Galapagos), Vincent Bouget (CSO, CentraleSupélec / MSc Biomedical Sciences), and Julien Duquesne (CTO, CentraleSupélec / MSc MVA, ENS Paris-Saclay). The company has raised 6.5 million euros in total funding, including support from the European Innovation Council’s EIC Accelerator, the EU’s flagship program for breakthrough deep-tech innovations.
PrecisemAb Biotech Co., Ltd.
PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. [Features of Core Technology (Antibody Lock)] ‧Higher masking ability and removal ability ‧Low immunogenicity ‧Prevention of anti-drug antibody binding ‧Prolonged serum half-life [Lead Product] PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. [Partnering] Through the (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials. | PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. | Company Overview Founded in October 2021, PrecisemAb Biotech was established by the late Professor Tian-Lu Cheng, former Vice President of Kaohsiung Medical University (KMU), as a KMU spin-off company. PrecisemAb focuses on applying the exclusively licensed Universal Antibody Lock Technology to develop next-generation precision antibody drugs with high specificity, low side effects, and enhanced therapeutic efficacy. Innovations & Advantages of the Universal Antibody Lock Platform The Universal Antibody Lock Technology integrates a Hinge + Linker structure that connects the VL/VH domains of an antibody. This unique design prevents antibodies from binding to healthy tissues until they reach the tumor microenvironment (TME). The Hinge-based lock, derived from human IgG1, serves as a masking mechanism, reducing unwanted interactions with normal tissues. The Linker, optimized through computational modeling, includes tumor-specific protease cleavage sites and spatial adjustment regions that ensure precise activation in the tumor microenvironment (TME). This mechanism enables antibodies to remain inactive in normal tissues and only activate when exposed to tumor-specific proteases, thereby minimizing off-target toxicity and enhancing therapeutic efficacy. By selectively triggering antibody activation at the tumor site, this technology significantly reduces side effects and improves treatment outcomes, ultimately enhancing patient quality of life. Compared to competing platforms, the Universal Antibody Lock Technology offers several key advantages. First, the human IgG1 hinge-based lock has low immunogenicity, reducing the risk of anti-drug antibody (ADA) formation and avoiding interference with drug efficacy. Second, the platform is highly versatile, allowing seamless integration into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs), which accelerates the development timeline for Lock-antibody drugs. Third, the linker design, incorporating tumor-specific protease cleavage sites and spatial adjustment regions, delivers the highest antibody activation rate globally in TME. The Universal Antibody Lock Technology has been adopted for industry collaboration. In May 2024, GlycoNex Biotech signed a non-exclusive licensing agreement with PrecisemAb, further demonstrating its applicability in antibody drug development. Drug Development (1) PrecisemAb’s lead drug, PSM101 (Lock-EGFR antibody), is designed for EGFR-expressing cancers, including head and neck cancer and colorectal cancer. The drug has successfully completed in vitro and in vivo efficacy and safety studies, cell line development, upstream process optimization (yield: 4.2 g/L), downstream process optimization, formulation research, and accelerated stability testing. PSM101 is planned for IND submission to the US FDA and TFDA in Q4 2026. (2) Additionally, PSM915 (Lock-TNF-α) has been evaluated in Biomedcode’s rheumatoid arthritis (RA) mouse model, demonstrating its ability to suppress RA disease progression and improve drug safety.
NanoTag Biotechnologies GmbH
Custom-tailored single-domain antibody solutions We provide high-quality single-domain antibodies (sdAbs) to advance research and biomedicine. From tailored sdAb discovery and innovative technologies to tools for immunofluorescence, super-resolution microscopy, and affinity purification, our solutions ensure reliability and precision. With custom-engineered nanobodies and protein production services, we empower you to tackle complex scientific challenges with confidence. Unlock the full potential of sdAbs with NanoTag Biotechnologies.
ITR Laboratories Canada Inc
Located in Montreal, Canada, ITR Laboratories is a full service CRO offering nonclinical toxicology testing for developing drugs. ITR’s GLP-compliant safety testing services can support your next product registration effort in any global market. We perform studies in general toxicology, inhalation, infusion, safety pharmacology, immunology and genetic toxicology. Lab support services include analytical, bioanalytical, ligand binding (PK, PD and biomarkers) assays, and flow cytometry. Over 30 years, ITR has grown from a small facility with 50 staff, to a mid-sized CRO with over 400 employees serving the global market. With over 6000 studies successfully completed, ITR continues to expand its facility and the expertise of its scientific staff. ITR is committed to providing the highest quality services to suit the needs of sponsors; our expert staff will continue to stay up-to-date with the latest technological developments to ensure we are always ready for new and challenging projects. | Located in Montreal, Canada, ITR Laboratories is a full service CRO offering nonclinical toxicology testing for developing drugs. ITR’s GLP-compliant safety testing services can support your next product registration effort in any global market. We perform studies in general toxicology, inhalation, infusion, safety pharmacology, immunology and genetic toxicology. We also offer juvenile toxicology services. Lab support services include analytical, bioanalytical, ligand binding (PK, PD and biomarkers) assays, and flow cytometry. Over 30 years, ITR has grown from a small facility with 50 staff, to a mid-sized CRO with nearly 500 employees serving the global market. With over 6000 studies successfully completed, ITR continues to expand its facility and the expertise of its scientific staff. ITR is committed to providing the highest quality services to suit the needs of sponsors; our expert staff will continue to stay up-to-date with the latest technological developments to ensure we are always ready for new and challenging projects. | Located in Montreal, Canada, ITR Laboratories is a full service CRO offering nonclinical toxicology testing for developing drugs. ITR’s GLP-compliant safety testing services can support your next product registration effort in any global market. We perform studies in general toxicology, inhalation, infusion, safety pharmacology, immunology and genetic toxicology. We also offer juvenile toxicology services. Lab support services include analytical, bioanalytical, ligand binding (PK, PD and biomarkers) assays, and flow cytometry. Over 35 years, ITR has grown from a small facility with 50 staff, to a mid-sized CRO with over 500 employees serving the global market. With over 6000 studies successfully completed, ITR continues to expand its facility and the expertise of its scientific staff. Our most recent expansion was completed in February of 2023 and added an additional 8 animal rooms for a total of 80 rooms. Specializing in inhalation toxicology, ITR has 22 exposure rooms with over 750 completed inhalation studies, ITR is ranked as the #1 inhalation CRO in the world. ITR is committed to providing the highest quality services tailored to the needs of sponsors; our expert staff continues to stay up-to-date with the latest technological developments to ensure readiness for new and challenging projects.
iRepertoire
Over the past decade, iRepertoire has developed gold standard technologies for immune repertoire sequencing. Our core technologies provide the ability to amplify expressed V(D)Js in B or T cells, and we offer the only technology that can measure all 7 immune chains simultaneously. We also offer a single cell solution to capture V(D)J rearrangements from rare cell populations. Beyond sequencing, iRepertoire now provides comprehensive data analysis services that accelerate biomarker discovery, advance disease research, and support IO drug development programs. iRepertoire is committed to creating cutting-edge technology and analytical solutions that adapt to the ever-changing immune sequencing landscape. | .
Instant NanoBiosensors Co. Ltd
Instant NanoBiosensors (INB) is an innovative precision medicine company specializing in ultra-sensitive protein-based blood tests for Alzheimer’s disease and gene-based solutions for leukemia through its INLab NGS Solution. Revolutionizing Alzheimer’s Diagnostics Leveraging our proprietary Fiber Optic Particle Plasmon Resonance (FOPPR™) technology, we provide a non-invasive, rapid, and cost-effective solution for the early detection of Alzheimer’s-related biomarkers. Our technology enhances diagnostic accuracy, accelerates drug development, and supports personalized medicine applications for medical institutions and pharmaceutical companies. INB is the only point-of-care testing (POCT) platform on the market that enables end-to-end solutions—from antibody analysis to ultra-sensitive assay development. This platform has been adopted by the EU-funded TAuimMunE (TAME) project as a key training tool for PhD researchers. Current blood biomarker diagnostic methods are often expensive, centralized, and require specialized personnel to operate. INB’s solution addresses these limitations by making early Alzheimer’s detection more accessible and affordable. Our goal is to provide a highly accessible and precise diagnostic platform that enhances patient care and therapeutic outcomes worldwide. Leukemia Precision Medicine: INLab NGS Solution In leukemia diagnostics, INB has developed a comprehensive NGS Precision Medicine Solution that streamlines the entire workflow—from sample processing to final report generation—with fully integrated instruments, reagents, and software. We have extensive experience collaborating with National Taiwan University Hospital, working closely with hematology and oncology specialists to develop clinically relevant diagnostic reagents. Our solution currently serves nearly 70% of leukemia patients in Taiwan and has also been adopted by Yale Medical Center in the United States. Key Advantages of Our Solution ✅ Enhanced Accuracy and Efficiency: Our proprietary DimerOff™ technology minimizes primer dimer formation and sequencing noise, producing cleaner, more accurate sequencing data. This significantly improves sensitivity for detecting MDS/AML-related mutations, ensures higher clinical reliability, reduces sequencing costs by more than 50%, and shortens the turnaround time to just three days. ✅ MRD Detection & MPN Monitoring: Our solution enables precise monitoring of measurable residual disease (MRD) and myeloproliferative neoplasms (MPN), supporting long-term patient management and treatment adjustments. ✅ Customizable Panels for Specific Clinical Needs: We work closely with clinicians and researchers to develop NGS panels tailored to specific research and diagnostic requirements. Our flexible approach optimizes mutation detection, enhances patient stratification, and reduces operational costs for both research and clinical applications. Through continuous innovation and strategic partnerships, INB is committed to transforming precision medicine and improving patient outcomes worldwide. We Are Seeking Partnerships With: International Distributors interested in bringing our innovative diagnostic solutions to global markets. Biotech Companies looking for co-development opportunities in assay and panel development. Pharmaceutical Companies seeking companion diagnostics solutions to support targeted drug development. Hospitals & CROs aiming to establish a comprehensive precision medicine system within their organization. Scientists & Research Institutions interested in collaborative grant applications. If you are interested in collaborating with us, we welcome the opportunity to discuss how INB’s cutting-edge solutions can support your research, clinical, and commercial objectives.